| Sandra L Schwefel Massie, RN LDCSW | |
|
108 N Lincon Avenue, Beaver Dam, WI 53916 | |
| (920) 887-8751 | |
| (920) 887-3977 |
| Full Name | Sandra L Schwefel Massie |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 38 Years |
| Location | 108 N Lincon Avenue, Beaver Dam, Wisconsin |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912082496 | NPI | - | NPPES |
| 39259700 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 701123 (Wisconsin) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Affiliated Counseling Center Llc | 5991790883 | 3 |
News Archive
Australia is one of only a few countries well prepared for an outbreak of bird flu in it's poultry population.
Minister for Public Health and Sport, Aileen Campbell MSP, today unveiled the latest innovation at the Golden Jubilee Foundation, a state of the art Motion Analysis Laboratory (MAL).
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.
Robert Rieveley, President of Biotech Holdings has announced that installation of pharmaceutic processing equipment required for Sucanon production is currently being completed. "Sucanon production is scheduled to begin within the week; our first production run is for 1.2 million Sucanon tablets, sufficient for 20,000 one-month Sucanon treatment packages.
› Verified 6 days ago
| Entity Name | Affiliated Counseling Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164568879 PECOS PAC ID: 5991790883 Enrollment ID: O20040419001617 |
News Archive
Australia is one of only a few countries well prepared for an outbreak of bird flu in it's poultry population.
Minister for Public Health and Sport, Aileen Campbell MSP, today unveiled the latest innovation at the Golden Jubilee Foundation, a state of the art Motion Analysis Laboratory (MAL).
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.
Robert Rieveley, President of Biotech Holdings has announced that installation of pharmaceutic processing equipment required for Sucanon production is currently being completed. "Sucanon production is scheduled to begin within the week; our first production run is for 1.2 million Sucanon tablets, sufficient for 20,000 one-month Sucanon treatment packages.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sandra L Schwefel Massie, RN LDCSW 108 N Lincon Avenue, Affiliated Counseling Center Llc, Beaver Dam, WI 53916 Ph: (920) 887-8751 | Sandra L Schwefel Massie, RN LDCSW 108 N Lincon Avenue, Beaver Dam, WI 53916 Ph: (920) 887-8751 |
News Archive
Australia is one of only a few countries well prepared for an outbreak of bird flu in it's poultry population.
Minister for Public Health and Sport, Aileen Campbell MSP, today unveiled the latest innovation at the Golden Jubilee Foundation, a state of the art Motion Analysis Laboratory (MAL).
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.
Robert Rieveley, President of Biotech Holdings has announced that installation of pharmaceutic processing equipment required for Sucanon production is currently being completed. "Sucanon production is scheduled to begin within the week; our first production run is for 1.2 million Sucanon tablets, sufficient for 20,000 one-month Sucanon treatment packages.
› Verified 6 days ago
Sarah Soltis, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: N7801 County Road Fw, Beaver Dam, WI 53916 Phone: 262-442-1406 | |
Katherine Marie Hulbert, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 809 Park Ave, Beaver Dam, WI 53916 Phone: 920-887-3171 Fax: 920-887-8622 | |
Ms. Amy Scott, CSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 707 S University Ave, Beaver Dam, WI 53916 Phone: 920-821-0071 | |
Mrs. Phyllis Ann Pleuss, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1200 North Center Street, Lutheran Social Services, Beaver Dam, WI 53916 Phone: 920-887-3172 |